|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ELOVL6 |
Gene summary for ELOVL6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ELOVL6 | Gene ID | 79071 |
| Gene name | ELOVL fatty acid elongase 6 | |
| Gene Alias | FACE | |
| Cytomap | 4q25 | |
| Gene Type | protein-coding | GO ID | GO:0000038 | UniProtAcc | A0A024RDK5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79071 | ELOVL6 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.79e-08 | -4.03e-01 | 0.0155 |
| 79071 | ELOVL6 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.21e-02 | -3.64e-01 | 0.096 |
| 79071 | ELOVL6 | HTA11_10711_2000001011 | Human | Colorectum | AD | 4.08e-02 | -3.86e-01 | 0.0338 |
| 79071 | ELOVL6 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.24e-07 | -4.12e-01 | 0.0674 |
| 79071 | ELOVL6 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.87e-05 | -5.77e-01 | 0.2585 |
| 79071 | ELOVL6 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.90e-20 | -5.42e-01 | 0.3005 |
| 79071 | ELOVL6 | F007 | Human | Colorectum | FAP | 4.30e-07 | -4.79e-01 | 0.1176 |
| 79071 | ELOVL6 | A002-C-010 | Human | Colorectum | FAP | 1.32e-09 | -3.54e-01 | 0.242 |
| 79071 | ELOVL6 | A001-C-207 | Human | Colorectum | FAP | 4.76e-10 | -4.75e-01 | 0.1278 |
| 79071 | ELOVL6 | A015-C-203 | Human | Colorectum | FAP | 2.34e-23 | -5.03e-01 | -0.1294 |
| 79071 | ELOVL6 | A015-C-204 | Human | Colorectum | FAP | 1.44e-14 | -5.47e-01 | -0.0228 |
| 79071 | ELOVL6 | A014-C-040 | Human | Colorectum | FAP | 1.89e-05 | -5.84e-01 | -0.1184 |
| 79071 | ELOVL6 | A002-C-201 | Human | Colorectum | FAP | 1.63e-19 | -5.13e-01 | 0.0324 |
| 79071 | ELOVL6 | A002-C-203 | Human | Colorectum | FAP | 3.09e-05 | -3.48e-01 | 0.2786 |
| 79071 | ELOVL6 | A001-C-119 | Human | Colorectum | FAP | 1.04e-11 | -5.58e-01 | -0.1557 |
| 79071 | ELOVL6 | A001-C-108 | Human | Colorectum | FAP | 1.96e-18 | -4.58e-01 | -0.0272 |
| 79071 | ELOVL6 | A002-C-205 | Human | Colorectum | FAP | 1.78e-21 | -5.45e-01 | -0.1236 |
| 79071 | ELOVL6 | A014-C-108 | Human | Colorectum | FAP | 2.49e-04 | -4.20e-01 | -0.124 |
| 79071 | ELOVL6 | A001-C-104 | Human | Colorectum | FAP | 4.89e-10 | -4.14e-01 | 0.0184 |
| 79071 | ELOVL6 | A015-C-005 | Human | Colorectum | FAP | 2.11e-05 | -3.63e-01 | -0.0336 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016053 | Colorectum | MSS | organic acid biosynthetic process | 76/3467 | 316/18723 | 7.88e-03 | 4.84e-02 | 76 |
| GO:00091504 | Colorectum | FAP | purine ribonucleotide metabolic process | 96/2622 | 368/18723 | 4.91e-10 | 1.20e-07 | 96 |
| GO:00061634 | Colorectum | FAP | purine nucleotide metabolic process | 100/2622 | 396/18723 | 1.45e-09 | 2.77e-07 | 100 |
| GO:00092593 | Colorectum | FAP | ribonucleotide metabolic process | 97/2622 | 385/18723 | 2.90e-09 | 5.07e-07 | 97 |
| GO:00725214 | Colorectum | FAP | purine-containing compound metabolic process | 101/2622 | 416/18723 | 1.11e-08 | 1.33e-06 | 101 |
| GO:00196933 | Colorectum | FAP | ribose phosphate metabolic process | 97/2622 | 396/18723 | 1.35e-08 | 1.51e-06 | 97 |
| GO:00091174 | Colorectum | FAP | nucleotide metabolic process | 105/2622 | 489/18723 | 3.52e-06 | 1.25e-04 | 105 |
| GO:00067534 | Colorectum | FAP | nucleoside phosphate metabolic process | 105/2622 | 497/18723 | 7.47e-06 | 2.25e-04 | 105 |
| GO:00091523 | Colorectum | FAP | purine ribonucleotide biosynthetic process | 42/2622 | 169/18723 | 1.17e-04 | 1.91e-03 | 42 |
| GO:00066313 | Colorectum | FAP | fatty acid metabolic process | 81/2622 | 390/18723 | 1.43e-04 | 2.24e-03 | 81 |
| GO:00092603 | Colorectum | FAP | ribonucleotide biosynthetic process | 43/2622 | 182/18723 | 3.23e-04 | 4.15e-03 | 43 |
| GO:00061643 | Colorectum | FAP | purine nucleotide biosynthetic process | 44/2622 | 191/18723 | 4.96e-04 | 5.71e-03 | 44 |
| GO:00463903 | Colorectum | FAP | ribose phosphate biosynthetic process | 43/2622 | 190/18723 | 8.40e-04 | 8.72e-03 | 43 |
| GO:00725223 | Colorectum | FAP | purine-containing compound biosynthetic process | 44/2622 | 200/18723 | 1.35e-03 | 1.24e-02 | 44 |
| GO:0001659 | Colorectum | FAP | temperature homeostasis | 38/2622 | 174/18723 | 3.16e-03 | 2.36e-02 | 38 |
| GO:01061061 | Colorectum | FAP | cold-induced thermogenesis | 32/2622 | 144/18723 | 4.85e-03 | 3.25e-02 | 32 |
| GO:01201611 | Colorectum | FAP | regulation of cold-induced thermogenesis | 32/2622 | 144/18723 | 4.85e-03 | 3.25e-02 | 32 |
| GO:19908451 | Colorectum | FAP | adaptive thermogenesis | 34/2622 | 157/18723 | 5.77e-03 | 3.69e-02 | 34 |
| GO:01201621 | Colorectum | FAP | positive regulation of cold-induced thermogenesis | 23/2622 | 97/18723 | 6.95e-03 | 4.26e-02 | 23 |
| GO:00091505 | Colorectum | CRC | purine ribonucleotide metabolic process | 74/2078 | 368/18723 | 2.58e-07 | 2.38e-05 | 74 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa01212 | Colorectum | CRC | Fatty acid metabolism | 14/1091 | 57/8465 | 1.17e-02 | 4.99e-02 | 3.38e-02 | 14 |
| hsa012121 | Colorectum | CRC | Fatty acid metabolism | 14/1091 | 57/8465 | 1.17e-02 | 4.99e-02 | 3.38e-02 | 14 |
| hsa012124 | Liver | HCC | Fatty acid metabolism | 45/4020 | 57/8465 | 1.05e-06 | 1.10e-05 | 6.09e-06 | 45 |
| hsa000622 | Liver | HCC | Fatty acid elongation | 20/4020 | 27/8465 | 4.58e-03 | 1.36e-02 | 7.55e-03 | 20 |
| hsa010402 | Liver | HCC | Biosynthesis of unsaturated fatty acids | 19/4020 | 27/8465 | 1.37e-02 | 3.33e-02 | 1.85e-02 | 19 |
| hsa012125 | Liver | HCC | Fatty acid metabolism | 45/4020 | 57/8465 | 1.05e-06 | 1.10e-05 | 6.09e-06 | 45 |
| hsa0006211 | Liver | HCC | Fatty acid elongation | 20/4020 | 27/8465 | 4.58e-03 | 1.36e-02 | 7.55e-03 | 20 |
| hsa010403 | Liver | HCC | Biosynthesis of unsaturated fatty acids | 19/4020 | 27/8465 | 1.37e-02 | 3.33e-02 | 1.85e-02 | 19 |
| hsa012128 | Oral cavity | OSCC | Fatty acid metabolism | 35/3704 | 57/8465 | 5.37e-03 | 1.29e-02 | 6.55e-03 | 35 |
| hsa0121213 | Oral cavity | OSCC | Fatty acid metabolism | 35/3704 | 57/8465 | 5.37e-03 | 1.29e-02 | 6.55e-03 | 35 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ELOVL6 | SNV | Missense_Mutation | novel | c.327C>G | p.Ser109Arg | p.S109R | Q9H5J4 | protein_coding | deleterious(0.05) | benign(0.287) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| ELOVL6 | SNV | Missense_Mutation | c.793N>A | p.Glu265Lys | p.E265K | Q9H5J4 | protein_coding | tolerated(0.2) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ELOVL6 | SNV | Missense_Mutation | c.39N>A | p.Phe13Leu | p.F13L | Q9H5J4 | protein_coding | deleterious(0.03) | benign(0.057) | TCGA-BH-A0HX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adrimycin | SD | |
| ELOVL6 | SNV | Missense_Mutation | novel | c.253N>G | p.Met85Val | p.M85V | Q9H5J4 | protein_coding | deleterious(0.01) | benign(0.038) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ELOVL6 | SNV | Missense_Mutation | c.778A>G | p.Lys260Glu | p.K260E | Q9H5J4 | protein_coding | tolerated(0.11) | benign(0.385) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| ELOVL6 | SNV | Missense_Mutation | c.226N>G | p.Phe76Val | p.F76V | Q9H5J4 | protein_coding | tolerated(0.51) | benign(0.01) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ELOVL6 | SNV | Missense_Mutation | c.272N>G | p.Thr91Ser | p.T91S | Q9H5J4 | protein_coding | tolerated(0.28) | benign(0.038) | TCGA-CM-6674-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| ELOVL6 | SNV | Missense_Mutation | novel | c.611N>T | p.Thr204Ile | p.T204I | Q9H5J4 | protein_coding | deleterious(0.02) | benign(0.012) | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ELOVL6 | SNV | Missense_Mutation | c.349N>C | p.Val117Leu | p.V117L | Q9H5J4 | protein_coding | tolerated(0.18) | benign(0.085) | TCGA-DY-A1DC-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Chemotherapy | capecitabine | PR | |
| ELOVL6 | SNV | Missense_Mutation | novel | c.690G>T | p.Gln230His | p.Q230H | Q9H5J4 | protein_coding | tolerated(0.06) | benign(0.005) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |